NEW YORK, NY--(Marketwired - July 12, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has been assigned two provisional patent applications from Memorial Sloan-Kettering Cancer Center (MSK). The Company's License, Development and Commercialization Agreement (License Agreement) with MSK, which already included issued patents that pertain to Actinium's Alpha Particle Immunotherapy (APIT) technology platform and drug preparation methods now includes these newly assigned provisional patent applications.
Kaushik J. Dave, Ph.D., MBA, Actinium's Chief Executive Officer said, "These provisional patent applications are a welcome addition to Actinium's intellectual property portfolio. We have been focused on the development of intellectual property on the production of Actinium-225, linking technologies that can be used in our APIT platform and methods of use and these provisional patents represent the potential extension of our IP beyond 2035."
The two provisional patent applications assigned to Actinium from MSK pertain to the labeling of monoclonal antibodies with Actinium-225 and the application of these Actinium-225 enabled antibodies for treating cancers. Actinium-225 is an alpha-emitting isotope used in the Company's drug candidate Actimab-A, which is intended to treat patients newly diagnosed with Acute Myeloid Leukemia (AML) over the age of 60. Actimab-A is a second generation therapy from Actinium's HuM195-alpha program, which has been studied in almost 90 patients in four clinical trials. Actinium's intellectual property portfolio consists of wholly-owned and licensed issued and pending patents related to isotope production methods, drug preparation methods specific to the labeling of anitobodies with Actinium-225, monocloncal antibody composition and production and the use of Actinium's technology in the treatment of cancer.
Sandesh Seth, Actinium's Executive Chairman stated, "We are pleased to announce these two additional provisional patent applications and thank Memorial Sloan Kettering Cancer Center for their continued efforts as part of our collaboration. Our APIT platform and Actinium-225 are strategically important assets to the Company that we believe will be of interest to biopharmaceutical companies seeking to enhance their antibody programs and therefore represents significant potential value to our shareholders. Most importantly, they represent potential new therapies that could improve the lives of the patients we are focused on improving through the development of targeted radioimmunotherapies."
About Alpha Particle Immunotherapy (APIT) platform
Actinium's Alpha Particle Immunotherapy (APIT) platform is a highly potent and selective form of targeted payload radioimmunotherapy. The APIT platform is based on attaching the powerful alpha emitting radioisotope Actinium-225 to monoclonal antibodies (mAbs), which are large molecules capable of binding specifically to cancer cells. By virtue of carrying alpha emitters, mAbs bring Actinium-225 directly to cancer cells where alpha emitters can selectively kill the targeted cell. Actinium-225 emits significant energy making it a potent against targeted cancer cells but this energy only travels extremely short distances limiting damage to healthy tissues. Due to the targeting of this energy by way of the mAbs bringing the alpha emitting isotopes directly to cancer cells, Actinium believes Actinium-225 enabled therapies will result in potentially more effective and at the same time tolerable therapies.
Actimab-A, Actinium's most advanced alpha particle immunotherapy program is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single arm multicenter trial. Actimab-A is being developed as a first line therapy and has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the Lintuzumab monoclonal antibody and Actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Lintuzumab is the humanized version of M195 and is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. Both the alpha particle technology and Lintuzumab were initially developed at Memorial Sloan Kettering Cancer Center.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.